For 2 decades fluoroquinolones have been found to be generally well-tolerated and safe. Adverse events may be inherent to the class or influenced by structural modifications. The commonest adverse events are gastrointestinal tract (GI) and central nervous system (CNS) reactions; nephrotoxicity and tendinitis are infrequent, but agents differ greatly in phototoxic potential. Fluoroquinolones are safe in elderly, human immunodeficiency virus -infected, and neutropenic patients, but because of possible effects on articular cartilage, they are not currently recommended for children or pregnant women. Four new agents have recently been licensed. Levofloxacin causes few GI or CNS adverse events and is minimally phototoxic. Sparfloxacin infrequently causes GI or CNS effects but is associated with relatively high rates of phototoxicity and prolongation of the electrocardiographic QT c interval (Q-T interval, corrected for heart rate). Grepafloxacin causes relatively high rates of GI effects, taste perversion, and QT c interval prolongation, but it is minimally phototoxic. Trovafloxacin is associated with a moderate rate of GI effects and a relatively high incidence of dizziness but has low phototoxic potential.
Since their introduction in the 1960s with nalidixic acid, FQs approved in the past 2 years by the U.S. Food and Drug Administration (FDA): levofloxacin, sparfloxacin, grepafloxaquinolone antimicrobial agents have undergone extensive synthetic and clinical development, resulting in improved antimicin, and trovafloxacin. crobial activity, pharmacokinetic features, and toxicity profiles [1, 2] . Nalidixic acid had limited use and frequently caused General Overview of Toxicity of FQ Antimicrobials adverse events [3] . The pyridopyrimidine and cinnoline derivaWith the exception of temafloxacin [5 -7] , FQs have proven tives introduced in the 1970s demonstrated broader antimicroto be a well-tolerated class of drugs [8, 9] , especially when bial spectra and better pharmacokinetic profiles. The most imcompared with other commonly prescribed antimicrobials [2, portant breakthrough, however, was development of the 10]. A review of safety results from 28 prospective, randomfluoroquinolones (FQs) in the 1980s, with broad antibacterial ized, double-blind, placebo-or active-controlled clinical trials spectra, excellent pharmacological properties, and a low incirevealed that in 22, FQ agents were not significantly different dence of serious adverse events [2 -4] . While the pharmacokifrom nonquinolone comparator agents or placebo in terms of netics and efficacy of these agents have improved, a major the proportion of patients experiencing adverse events, and in ongoing aim has been to further reduce adverse events [4] .
5 studies FQ agents were significantly superior to comparator This paper will review the safety profile of FQ agents, assess agents [11] . differences among class members, and address the safety of Adverse events caused by various FQs are generally compathese agents in special populations. We will focus on the newest rable, although for individual agents the incidence and type may differ [1, 12] . Reported rates of adverse events depend on definitions used and how information was obtained. Prospective days to 500 mg once daily for 14 days, the drug was generally changes, confusion, delirium, psychosis, tremor,
well-tolerated and safe [16 -25] , with fewer GI, CNS, and derseizure matologic adverse events occurring than with use of ofloxacin Hepatic Transient rise in level of liver function enzymes, [15, 26] . North American clinical trials of levofloxacin found an cholestatic jaundice, hepatitis, hepatic failure Renal Azotemia, crystalluria, hematuria, interstitial overall incidence of possible or probable drug-related adverse nephritis, nephropathy, renal failure events of 2.0% -9.9% [16 -25] , with nausea (1% -3%) and rator drugs. There were no clinically significant changes in laboratory test values, including liver and renal function, blood NOTE. Occurrence and incidence of adverse events vary among the FQ agents. QT c interval Å Q-T interval, corrected for heart rate.
glucose, and hematologic parameters, in patients treated with levofloxacin. [4] . Adverse effects such as GI symptoms and arthropathy do Sparfloxacin not appear to be affected by structural modification. Crystalluria, CNS symptoms, and phototoxicity are highly related to Sparfloxacin (Zagam; Rhône-Poulenc Rorer Pharmaceutichemical changes [4, 13] . Chemical structures of various FQs cals, Collegeville, PA) is a difluorinated oral quinolone that are shown in figure 2 .
differs from other agents by having an amino group at the C-5 position of the quinolone ring. It has increased potency against aerobic gram-positive cocci, particularly Streptococcus pneuOverview of Safety with the Newest FQs moniae, and has recently been approved for treatment of comLevofloxacin munity-acquired pneumonia (CAP) and acute bacterial exacerbations of chronic bronchitis (ABECB) [27] . Levofloxacin (Levaquin; Ortho-McNeil Pharmaceutical, Raritan, NJ), the active 1-isomer of racemate ofloxacin, is apIn a series of 1,040 patients treated for lower respiratory tract infections in European trials [28] , sparfloxacin was at proximately twice as potent as ofloxacin against many susceptible pathogens [14] . It is available in both oral and parenteral least as well tolerated as comparator antibacterials (amoxicillin, amoxicillin/clavulanate, ofloxacin with amoxicillin, and erythformulations and has been approved for a broad range of indica- Figure 1 . Summary of quinolone structure -side effect relationships. Comparisons are from high to low (diFPh Å difluorophenyl; GABA Å gamma-aminobutyric acid; NSAID Å nonsteroidal antiinflammatory drug; pip Å piperazinyl; pyrr Å pyrrolidinyl; subst Å substituents [see {4}]). Reprinted from The Journal of Antimicrobial Therapy with permission from Oxford University Press. ported). The percentage of patients discontinuing therapy because of an adverse event was similar for patients treated with sparfloxacin and those treated with comparator agents.
To date, few published articles describe the toxicity profile of sparfloxacin, but data are available from abstracts and postmarketing surveillance. Adverse events were evaluated in six North American phase III trials of patients with respiratory or complicated skin and skin structure infections [29] . The most frequently reported drug-related adverse events that occurred at statistically significant different rates for sparfloxacin vs. one of several comparator agents (erythromycin, cefaclor, ofloxacin, clarithromycin, or ciprofloxacin) were photosensitivity reactions (7.9% vs. 0.9%; P õ .001); diarrhea (4.6% vs. 6.7%; P Å .015); nausea (4.3% vs. 10.3%; P õ .001); insomnia (1.9% vs. 5.6%; P õ .001); pruritus (1.8% vs. 0.8%; P Å .024); abdominal pain (1.8% vs. 3.5%; P Å .004); taste perversion (1.4% vs. 2.9%; P Å .004); prolongation of QT c interval (Q-T interval, corrected for heart rate; 1.3% vs. 0.5%; P Å .035); and vomiting (1.3% vs. 2.6%; P Å .019). Adverse events that were serious or that led to discontinuation of therapy occurred in 2.7% and 6.6% of sparfloxacin-treated patients, respectively, and 3.5% and 8.9% of the comparators [29] . No clinically important laboratory abnormalities were detected. These results are similar to those previously reported from six similar European phase III comparative trials, except that the rate of sparfloxacin-associated phototoxicity was higher than in the European studies [30] .
Although sparfloxacin prolonged the QT c interval by a mean of 10 msec, there were no associated clinically significant cardiac arrhythmias. Because of reported incidents of torsades de pointes detected post-marketing, sparfloxacin is contraindicated for patients receiving other QT c interval -prolonging drugs and should be avoided by those with a QT c interval prolonged for any other reason.
Grepafloxacin
Grepafloxacin (Raxar; GlaxoWellcome, Research Triangle Park, NC) is characterized by an N-1 cyclopropyl group, a C-5 methyl group, and a C-7 piperazinyl moiety with an attached methyl group. Grepafloxacin has enhanced activity against ical organisms. It is approved for oral treatment of mild to moderate infections, including ABECB, CAP, uncomplicated gonorrhea, and nongonococcal urethritis and cervicitis caused romycin). During treatment for CAP, 13.7% of patients treated with sparfloxacin and 17.7% treated with a comparator antibacby Chlamydia trachomatis [31] . Grepafloxacin has been used by over 20,000 patients worldterial experienced a drug-related adverse event. In patients treated for acute exacerbation of chronic obstructive pulmonary wide. In three double-blind comparative clinical trials involving patients with respiratory tract infections, the proportion of padisease, 9.5% and 13.2% treated with sparfloxacin and amoxicillin/clavulanate, respectively, experienced a drug-related adtients reporting adverse events was similar among patients treated with grepafloxacin (300 -600 mg once daily for 7 -verse event. Among all sparfloxacin-treated patients, 11.4% had GI adverse events (with diarrhea [2.6%] the most commonly 14 days), ofloxacin, or amoxicillin. The most common events associated with grepafloxacin included nausea (£10%), headreported), Ç2% experienced phototoxicity, and 4.2% reported CNS effects (with insomnia [1.3%] the most frequently reache (£3%), diarrhea (£3%), dizziness (£2%), and rash (£2%); these rates were similar to those for comparator drugs, tential adverse events reported include sweating, flushing, abdominal cramping, rash, and pruritus [38] . Toxicity studies except that nausea was more frequent with use of grepafloxacin than with use of amoxicillin (2%) or ofloxacin (£1%). Abnorhave demonstrated an increased incidence and intensity of lightheadedness, headache, nausea, and emesis as a single oral mal laboratory parameters, primarily increases in hepatic enzyme levels, were reported for 12% -16% of patients treated dose is increased from 30 to 1,000 mg and multiple oral doses are increased from 100 to 300 mg daily [38 -40] . with grepafloxacin (300 mg daily), vs. 7% -11% receiving ofloxacin [32] . During clinical trials, õ2% of patients receiving Of note, trovafloxacin minimally interferes with the cytochrome P450 system and does not substantially interact with 400 mg of grepafloxacin daily and 5.4% of patients receiving 600 mg daily discontinued therapy because of adverse events warfarin or theophylline. Coadministration with intravenous morphine reduces the absorption of oral trovafloxacin, and [33] . Photosensitivity has been reported less frequently than with sparfloxacin. Drug-related cardiac adverse events were doses of these two agents should be separated accordingly [36, 41] . Available data suggest trovafloxacin's phototoxic potential reported in õ1% of grepafloxacin-treated patients, although the average increase in QT c interval was 10 msec [33] .
is [9, 45] . Clostridium difficile -associated abdominal pain (2.2%), nervousness (2.2%), and insomnia (3.3%) [35] . Neither of these studies addressed the potential colitis is uncommon with FQs, perhaps because of their minimal effect on anaerobic flora [11, 42] . Based on data reported for QT c interval prolongation.
to manufacturers or derived from clinical trials, the estimated rank order for agents in causing GI adverse events is as follows:
Trovafloxacin fleroxacin, grepafloxacin ú trovafloxacin ú sparfloxacin ú pefloxacin ú ciprofloxacin, levofloxacin ú norfloxacin ú enTrovafloxacin (Trovan; Pfizer, New York), with a trifluoronaphthyridone structure, is not strictly a quinolone but is generoxacin ú ofloxacin [10, 11, 15, 27, 31, 36, 46, 47] . To date, no one feature of the FQ structure has been associated with ally classified as an FQ. Compared to older FQs, trovafloxacin demonstrates increased activity against aerobic gram-positive adverse GI effects [4] . GI disorders were the most common drug-related adverse cocci, most notably S. pneumoniae, as well as anaerobic organisms. Trovafloxacin, available in oral and intravenous formulaevents in clinical trials of levofloxacin (5.1%); specific complaints included diarrhea (1.2%), nausea (1.2%), flatulence tions, is approved for multiple indications, including CAP, nosocomial pneumonia, ABECB, uncomplicated urinary tract (0.5%), abdominal pain (0.3%), dyspepsia (0.3%), taste perversion (0.2%), and vomiting (0.2%) [15 -25] . In clinical trials of infections, skin and skin structure infections, bacterial prostatitis, and complicated intra-abdominal infections, including postsparfloxacin, the most frequently reported GI adverse events were diarrhea (4.6%), nausea (4.3%), dyspepsia (2.3%), absurgical infections and gynecologic and pelvic infections [36] . Trovafloxacin is not soluble in aqueous solution; the intravedominal pain (1.8%), vomiting (1.3%), and flatulence (1.1%) [27] . Comparative trials have demonstrated adverse GI event nous formulation is alatrofloxacin, the L-Ala-L-Ala prodrug of trovafloxacin, which is rapidly converted to trovafloxacin in rates for sparfloxacin that are similar to those of cefaclor [48] and 2.5-to 5-fold lower than for erythromycin [49] . The incivivo [37] .
Data about adverse events associated with trovafloxacin are dence of nausea with sparfloxacin (4.0% -4.4%) was found to be approximately one-third as high as for ofloxacin (10.2%) limited. In multidose clinical efficacy studies of ú6,000 patients worldwide, therapy was discontinued for 5% because or ciprofloxacin (13.1%) [50, 51] . GI adverse events are also the most frequently reported in of adverse events thought to be drug-related [36] . The most frequently reported adverse events associated with trovafloxagrepafloxacin clinical trials and include nausea (11% -16%), diarrhea (3.5% -4%), abdominal pain (2%), vomiting (2% -cin involve the CNS and GI tract and include dizziness (3% -11%), lightheadedness (1% -4%), headache (1% -5%), nausea 6%), dyspepsia (1.5% -3%), anorexia (1% -2%), and constipation (1% -2%) [31] ; a metallic taste was reported by 9% and (4% -8%), vomiting (1% -3%), and diarrhea (2%). Other po-
01-20-99 07:41:30 cida UC: CID 18% of patients receiving 400 mg and 600 mg daily, respecyears of age indicated a lower incidence of dizziness (3.1%) and lightheadedness (0.6%). tively. The manufacturer noted trends suggesting a reduced incidence of nausea and taste perversion if the dose is adminis-
The mechanism of quinolone-associated CNS toxicity has not been fully elucidated but may involve gamma-aminobutyric tered in the evening [33] . Trovafloxacin is associated with a relatively low incidence of adverse GI events, with nausea acid (GABA). Inhibition of binding of GABA to GABA A receptors in the CNS results in CNS stimulation [1] . This charac-(4% -8%), vomiting (1% -3%), diarrhea (2%), and abdominal pain (1%) the most frequently reported [36] .
teristic, however, is not unique to the quinolones; penicillins, cephalosporins, and carbacephems also antagonize this neurotransmitter, causing neurotoxic effects [52] . Experiments in mice show binding of FQs to GABA receptors is enhanced by CNS 4-biphenylacetic acid, an active metabolite of the nonsteroidal anti-inflammatory drug fenbufen [59] . CNS disturbances are the second most commonly reported adverse events with FQs [4, 11] , with an overall incidence of
The primary excitatory effects of FQs in the CNS may also operate via N-methyl-D-aspartate and adenosine-receptor 1% -2% [10, 26, 27, 52] . Symptoms include headache, dizziness, and drowsiness, which usually occur on the first day of mechanisms or by activation of excitatory amino acid receptors. Preclinical studies in mice showed the following trend in epitherapy and resolve after discontinuation of the drug therapy [10] . Other reported CNS effects include abnormal vision, restleptogenic activity: enoxacin ú norfloxacin ú ciprofloxacin ú ofloxacin § levofloxacin [1, 60] . Neither grepafloxacin nor lessness, sleep disorders, agitation, acute organic psychosis, confusion, and delirium [4, 10, 45] . Convulsions and seizures trovafloxacin or alatrofloxacin induced convulsions in mice when administered in high doses in conjunction with fenbufen have occurred rarely, and usually in the setting of predisposing factors (e.g., epilepsy, cerebral trauma, or anoxia), metabolic [32, 36] . No single model for predicting epileptogenic activity of the FQs has completely predicted clinical experience. imbalance, or concomitant therapy with interacting agents (e.g., theophylline or nonsteroidal anti-inflammatory drugs) [1, 10 - The relative incidence of CNS adverse events of FQs may be related to their chemical structures. The R 7 side chain sub-12, 53]. Convulsions during FQ therapy usually develop 3 -4 days after the start of treatment and resolve with its discontinuastituent appears to have the greatest influence on the degree of GABA binding inhibition (figure 1); a bulky side chain lowers tion [42] ; they have occurred during treatment with enoxacin, pefloxacin, ofloxacin, ciprofloxacin, and norfloxacin [12, 45] .
binding affinity for the GABA receptor [4] . FQs with an unsubstituted piperazinyl ring (e.g., ciprofloxacin, enoxacin, and norThe reported overall trend in incidence of drug-related CNS adverse events is as follows: fleroxacin ú trovafloxacin ú floxacin) exhibit high binding affinity [13] . Lipophilicity and ability to cross the blood-brain barrier may also play a role in grepafloxacin ú norfloxacin ú sparfloxacin ú ciprofloxacin ú enoxacin ú ofloxacin ú pefloxacin ú levofloxacin [10, 11, CNS effects [4] . 15, 27, 29, 31, 36, 46, 47] . Symptoms vary somewhat for individual agents. Acute psychosis has been associated with Liver ofloxacin [54] and ciprofloxacin [55, 56] , and two cases of confusion and delirium have been attributed to pefloxacin [57] .
Liver enzyme abnormalities have been noted in 2% -3% of patients receiving FQ therapy [11, 46] . Elevations in serum Recent studies [18, 20 -22, 24, 25] have shown a low incidence (0.2% -1.1%) of CNS adverse events associated with transaminase and alkaline phosphatase levels are most common [11, 61] ; these are usually mild and reversible with discontinualevofloxacin and a slightly higher rate with sparfloxacin (1.9% to 4.2%) [27, 29] . The North American trials showed sparfloxtion of the therapy. On the basis of crude pooled estimates of data supplied by manufacturers, elevated levels of serum acin was associated with somewhat lower rates of dizziness and insomnia but a higher rate of headaches than were compaaspartate aminotransferase, alanine aminotransferase, or alkaline phosphatase occurred in 24.9, 24.0, and 17.8 patients per rators [29] . In direct comparisons with ofloxacin, sparfloxacin was associated with a lower rate of headaches (4.2% vs. 2.9%) 1,000 treated with ciprofloxacin, ofloxacin, and pefloxacin, respectively [46] . These liver enzyme abnormalities rarely led to [58] and insomnia (4.7% vs. 1.1% in one study and 14.9% vs. 1.5% in another) [50, 58] . CNS effects of grepafloxacin include discontinuation of therapy. The largest safety database available for any FQ is that for dizziness (4.3% -5.4%), somnolence (1% -1.5%), and nervousness (0.6% -1.7%) [31] . Trovafloxacin has a higher rate of ciprofloxacin, which has been administered to nearly 80,000 patients in clinical trials and, as of 1993, had been prescribed CNS effects, including dizziness (3% -11%), lightheadedness (2% -4%), and headache (1% -5%) [36] . These symptoms are to Ç80 million patients [8] . Spontaneous reports showed that 144 ciprofloxacin-treated patients had serious abnormalities in generally mild, last only a few hours, and may resolve with continued dosing; the incidence may be reduced if trovafloxacin liver function test values; small numbers of patients also developed hepatitis, liver necrosis, or hepatic insufficiency or failure. is taken at bedtime or with food. CNS symptoms with trovafloxacin have occurred more frequently in women and subTwo cases of cholestatic jaundice, possibly induced by ciprofloxacin, have been reported [62, 63] of toxic effects on skin have been reported, photosensitivity none of which necessitated discontinuation of therapy. Elevated reactions of two types have received the most attention. Phototransaminase levels were found in Ç2% of patients treated allergic reactions are rare, require previous exposure to the with sparfloxacin in the North American trials [29] . Clinical offending agent, and are manifest only a day or more after trial data for 2,500 patients treated with grepafloxacin demonexposure. Phototoxic reactions, by contrast, are more common, strated increased levels of hepatic transaminases, gamma-glutacan occur on initial exposure in anyone given a sufficient dose myl transpeptidase, and alkaline phosphatase in õ1% [31] .
of the offending drug and a high enough ultraviolet (UV) expoAmong 140 patients treated with trovafloxacin for 28 days, 9% sure, and develop within a few hours [67] . The mechanism of had asymptomatic increases in hepatic transaminase levels to phototoxicity appears to relate to photodegradability of individ- §3 times normal, but they returned to normal within 2 months ual FQs and their ability to induce oxygen singlets and free following discontinuation of therapy [36] .
radicals [42] . These reactive species are thought to attack cellular lipid membranes, initiating the inflammatory process [68] . Persons with fair skin are more susceptible than those with Urinary Tract darker skin. Photosensitivity reactions have been reported for most FQs Nephrotoxicity as a consequence of FQ therapy is uncombut differ in severity and incidence [4] . Clinical manifestations mon [4, 11, 12] , but there have been some reports of hematuria, range from mild erythema of sun-exposed areas to extensive interstitial nephritis, or acute renal failure [11, 61] . Nearly all and severe bullous eruptions. Reactions may follow exposure reported cases of acute renal failure have involved patients to direct or indirect sunlight (e.g., through glass or in shade), over 50 years of age, and in most instances the patients were as well as from UV (especially UVA) lamps. They generally ú65 years of age [45] . Renal failure may be due to a hypersenappear within a few days of the start of therapy but can occur sitivity reaction, as reported for ciprofloxacin, or a direct toxic up to 3 weeks after its discontinuation, and they usually subside effect, as reported for norfloxacin [45] . Adverse renal reactions within 1 month [11, 12, 42, 45] . Topical sunblockers that screen to ciprofloxacin are uncommon [8] but have included renal against both UVA and UVB may afford some protection, but failure (91 patients, of whom 12 required dialysis); elevated covering the skin with clothing or avoiding the outdoors is serum creatinine and blood urea nitrogen levels (63 patients); safer. nephritis (23 patients, including 2 with consequent renal fail-
The approximate order for phototoxic potential among the ure); and a renal tubular disorder (1 patient). The incidence FQs is as follows: lomefloxacin, fleroxacin ú sparfloxacin ú of an elevated serum creatinine level related to therapy with enoxacin ú pefloxacin ú ciprofloxacin, grepafloxacin ú norciprofloxacin, norfloxacin, ofloxacin, and pefloxacin ranges floxacin, ofloxacin, levofloxacin, and trovafloxacin [4, 8, 13 , from 0.2% to 1.3% [11] . The rate for ofloxacin (1.3%) was 15, 27, 29, 31, 36, 69]. Marked differences in phototoxic potenslightly higher than for the other FQs (0.2% -0.8%). Incidences tial are largely related to the X 8 substituent (figure 1) [4] . The of azotemia with ciprofloxacin, ofloxacin, and pefloxacin highest frequency of phototoxicity occurs when this position ranged from 1.8 to 13.1 per 1,000 patients treated [46] . is substituted by a halogen, especially fluorine; fleroxacin [70] , Crystalluria has been linked to FQ solubility in urine, lomefloxacin [71] , and sparfloxacin [29] all have a CF group which is pH-dependent. It has been observed in rats and in the X 8 position [4] . In addition, FQs with a bulky side chain monkeys, under urinary pH conditions that do not usually or a methyl group at R 5 are more likely to cause phototoxicity exist in humans [12] . In the normally acidic urine of humans, than would be predicted solely by the X 8 group [4] . crystalluria is rare [42] and not necessarily a cause of renal Fleroxacin demonstrates a dose-related frequency of photodamage [4, 11, 12, 45] . Nonetheless, patients should be well toxicity ranging from 0.6% at 200 -400 mg daily to 16% with hydrated, and alkalinity of urine should be avoided during 800-mg doses [47] . Photosensitivity occurred in 2.4% of 2,869 FQ therapy. Nearly all FQs are zwitterionic, owing to a basic lomefloxacin recipients and was judged to be drug-related in amine group in the R 7 side chain, making them least soluble 1.7% of cases [72] . Pooled data for pefloxacin, which has a at physiological pH [4] .
CH group in the X 8 position, indicate a phototoxicity frequency Changes in molecular structure aimed at improving water of 9.3 per 1,000 patients [46] . solubility in this pH range would minimize risk of crystalluria.
Phototoxicity has been the most frequent and important adThese include alkyl substitution of the R 7 substituent and use verse event associated with sparfloxacin therapy. Studies conof CF, CCl, CCF 3 , and COMe as the X 8 substituent ( figure 1) ducted in Japan, usually at dosages of 100 mg daily, revealed [4] . Crystalluria, interstitial nephritis, and acute renal failure phototoxicity in about 1% -2% of subjects. õ30 years of age and presents with pain, stiffness, and jointIn the North American trials the overall rate of photosensitivswelling. Onset is in the first few days of treatment, and the ity reactions to sparfloxacin was 7.9%, compared with a comarthropathy usually resolves within a few days or weeks after bined rate of 0.9% for five different comparators [29] . Most discontinuation of the treatment [1, 84] . The potential for quinreactions were mild (4.2%) or moderate (3.4%), but a few olone-induced arthropathy is a class effect, and structural modi-(0.6%) were severe. Because of the potential for phototoxic fication may not reduce this risk [4] . Chondrotoxicity has been reactions, patients must avoid exposure to direct or indirect observed in animal studies, but there is little evidence of clinisunlight or artificial UV light during and for 5 days following cally important quinolone-induced arthropathy in humans [1, sparfloxacin therapy [27]. 4, 85] . For levofloxacin, data from preclinical and phase I -II studies More recently, the possibility of tendinitis and tendon rupture indicate a minimal phototoxic potential, similar to that of associated with FQs has been raised [85 -90] . A survey conofloxacin and ciprofloxacin [14, 73] . Only one of 3,490 subjects ducted in France between 1985 and July 1992 found tendon had a potentially phototoxic reaction [73] . Studies of the reladisorders in 100 patients, including 31 with tendon rupture tive phototoxic effect on mice of a 200-mg/kg dose of various [89] . As of October 1994, 25 cases of FQ-associated tendon FQs found evidence of toxicity with use of sparfloxacin, lorupture were reported to the FDA, 22 of which had occurred mefloxacin, and to a lesser degree, enoxacin; ofloxacin, cioutside the United States [88] . Four cases of Achilles tendinitis profloxacin, and grepafloxacin had slight or no effects [74] .
complicating FQ treatment in the Netherlands have been deClinical trial data for grepafloxacin regimens (400 -600 mg scribed [91] . Tendon disorders have most often involved the daily) showed photosensitivity in õ2% of patients [31] . CurAchilles, with some occurring in the shoulder joint or hand rently available data suggest grepafloxacin has weak photosen- [88 -91] . Symptoms may begin from 1 to 42 days (average, sitizing potential, similar to that of ciprofloxacin [75] . In studies 13 days) after the start of FQ treatment and may occur after of mice, trovafloxacin caused only mild photosensitivity reacthe offending agent has been withdrawn [88 -90] . tions, and preliminary evaluations in humans suggest a lower
In contrast to arthropathy, tendon disorders or rupture generphototoxic potential for trovafloxacin than for lomefloxacin ally occurs in individuals ú50 years of age [84] , although or even ciprofloxacin [68, 76] . Phototoxicity was observed in reports include those from 25 to 84 years old [88, 89] . More õ0.03% (two) of 7,096 patients treated with trovafloxacin [36] men than women are affected, and concomitant use of corticoin clinical trials, making it among the least phototoxic FQ steroids appears to increase the risk [88, 89] . In the French agents.
series [89] , the clinical course of patients with tendon disorders Other skin reactions during FQ treatment are uncommon.
was usually favorable, although symptoms persisted for ú2 Occasionally reported reactions include rash, pruritus, urticaria, months in one-third of cases. Among patients reported to the vasculitis, edema, blue-black pigmentation of the legs, erup-FDA, 11 of 25 were hospitalized, had surgical repairs, or had tions with hemorrhagic bullae, and Henoch-Schönlein purpura a prolonged period of disability [88] . [46, 61, 77, 78] .
Specific agents reported to cause tendon disorders include norfloxacin, ciprofloxacin, pefloxacin, enoxacin, and sparfloxImmune System acin [30, 90, 92] . During preclinical development studies with levofloxacin, one case of possibly drug-related tendinitis was Hypersensitivity reactions, often with skin manifestations, reported; tendon rupture was not reported for levofloxacin in have occurred at a frequency of 0.6% -1.4% in FQ clinical trials clinical trials [16 -25] . Postmarketing surveillance in Japan and [10] . Erythema, pruritus, urticaria, and rash may be caused by Europe has uncovered occasional cases of tendinitis and tendon allergic reaction or a histamine-release phenomenon [79] . Fatal rupture associated with sparfloxacin. In the French sparfloxacin hypersensitivity vasculitis has occurred during ciprofloxacin pharmacovigilance data, estimated rates were 0.7 and 0.005 and ofloxacin therapy [43, 80] , and cutaneous erythema, itchper 1,000 treated patients, respectively [30] . Postmarketing suring, and a burning sensation have been reported to occur during veillance will be necessary to assess association with grepintravenous infusion of ciprofloxacin [81] . Serum sicknessafloxacin or trovafloxacin. Until additional information is availlike illness has also been reported in association with ciable, the FDA recommends that patients discontinue FQ profloxacin use [82] .
therapy at the first sign of tendon pain or inflammation and Anaphylactoid and anaphylactic reactions have been obrefrain from exercise until the diagnosis of tendinitis can be served from 5 minutes to 1 hour following FQ administration, confidently excluded [86 -88] . MRI may be useful for early in an estimated 0.46 to 1.2 cases per 100,000 [42, 45] . History detection and monitoring of tendinitis or tendon degeneration of hypersensitivity to one quinolone precludes or at least requires extreme caution with the use of another [12, 42] . [90] .
/ 9c61$$fe14 01-20-99 07:41:30 cida UC: CID CID 1999;28 (February) Fluoroquinolone Toxicity Profiles Cardiovascular System dren and growing adolescents [1, 88, 97, 98] . The mechanism of this chondrotoxicity is largely unknown [1, 85, 97, 99] . Systolic and diastolic hypotension has been noted in animals Despite concerns about toxicity, pediatric patients have refollowing rapid intravenous administration of most quinolones, ceived FQ therapy on a compassionate basis and in clinical probably as a result of histamine release [12] . In humans, hypotrials in special situations [97, 100, 101] . In one analysis, comtension, tachycardia, syncope, and migraines have followed prehensive clinical, MRI, and histopathologic monitoring of 18 oral administration of quinolones [12, 43] . Because QT c interpatients aged 6 -24 years for up to 22 months after a 3-month val prolongation [93] was noted during preclinical development course of ciprofloxacin therapy demonstrated no evidence of of sparfloxacin, careful electrocardiographic evaluation was FQ-induced arthropathy [97] . Review of several published peconducted in subsequent clinical trials. These revealed that diatric clinical trials involving ú1,000 prepubertal children 1.2% to 3% of sparfloxacin-treated patients experienced a porevealed good to excellent efficacy, with mild and reversible tentially clinically important QT c interval prolongation, to adverse events in 5% -15% of patients [101] . Reversible ar- §500 msec [29, 94, 95] . The magnitude of change appears thropathies were reported to occur in young patients with cystic dose-related, with a mean prolongation of QT c interval of 2% -fibrosis treated with ciprofloxacin (8 of 634; 1.3%) or pefloxa-8% associated with doses from 100 mg daily to 400 mg daily, cin (9 of 63; 14%). Some patients who had joint manifestations respectively. This appears less than that associated with erythwith pefloxacin therapy later tolerated ofloxacin without probromycin therapy [92, 94] , and QT c interval prolongation due lems [85] . to sparfloxacin generally has not been associated with clinical
The 1991 worldwide ciprofloxacin compassionate-use protosymptoms, cardiac arrhythmias, or other cardiovascular events.
cols involved 634 children aged 3 days to 17 years [100], One case of torsades de pointes leading to cardiopulmonary most of whom had an acute pulmonary exacerbation of cystic resuscitation was reported as probably associated with sparfibrosis. Mean oral and intravenous daily doses of ciprofloxacin floxacin therapy [96] .
were 25.2 mg/kg and 7.0 mg/kg, respectively. Eight children An international safety board reviewed data collected from (1.3%), all of whom had cystic fibrosis, had arthralgia that Ç750,000 patients treated with sparfloxacin as of May 1995 was reversible upon discontinuation of treatment. In the 1997 [94] . Seven serious adverse cardiovascular events were recumulative data from worldwide ciprofloxacin compassionateported, all in patients with an underlying cardiac condition.
use protocols involving 1,795 case reports, 26% of the patients The adverse cardiovascular event rate was not significantly were 12 -17 years of age, and 28% had cystic fibrosis. Arthraldifferent between sparfloxacin-treated patients and those who gia occurred in 31 (1.5%) of 2,030 treatment courses, but no received comparator antibacterials. The international safety unequivocal case of ciprofloxacin-induced arthropathy was board concluded that the QT c interval prolongation was not a documented [85] . In another ciprofloxacin treatment study cause for concern, but coadministration of sparfloxacin with [102] , only five of 202 children with cystic fibrosis under 18 medications known to increase the QT c interval or to induce years of age experienced arthralgia. Arthralgias have been rebradycardia should be avoided, and concomitant administration ported by cystic fibrosis patients treated with antimicrobials of amiodarone or sotalol was contraindicated.
other than FQs and may also be due to underlying disease In preclinical and clinical studies, levofloxacin was not assoprocesses [100, 101] . ciated with QT c interval prolongation. Grepafloxacin caused Less information is available for other FQs. No arthropathies QT c interval prolongation in clinical trials [31] , but the magniwere observed among 37 patients from 2 to 20 years of age tude of effect is unclear. Presently, grepafloxacin is contrainditreated with ofloxacin [45] . At least one case of destructive cated in patients with known QT c interval prolongation or those polyarthropathy has been reported, involving a 17-year-old concomitantly treated with other medications that may increase atopic boy who received pefloxacin (800 mg/d for 3 months) the QT c interval or induce torsades de pointes, unless appro- [103] . A review of FQ use in more than 7,000 skeletally immapriate cardiac monitoring is available. It is not recommended ture patients [85] concluded that reversible episodes of arthralfor use in patients with ongoing proarrhythmic conditions. One gia do not lead to long-term sequelae when treatment with the study found no clinically significant abnormal vital signs or offending agent is discontinued. Thus, prospective studies of electrocardiographic changes during intravenous infusion of selected quinolone agents for therapy in children seem justified, alatrofloxacin in doses up to an equivalent dose of 300 mg of and the FDA has encouraged such studies [104] . trovafloxacin [37] . Clinical trials data cited in trovafloxacin product information do not include occurrences of a prolonged QT c interval. There is relatively little published information (three times daily) of levofloxacin. Among 10 HIV-infected subjects who were not receiving concomitant zidovudine treatregarding toxicity of FQs for patients ú55 years of age, but it is likely that they are safe. In a summary of clinical data for ment [108] , the most commonly reported adverse events were equally frequent in the levofloxacin and placebo groups and oral ciprofloxacin [105] , nearly one-fourth of the 1,652 patients were ú70 years old. There was a tendency for all adverse involved the GI tract (9 subjects in each group), CNS (3 patients in each group), and skin (2 levofloxacin-treated and 4 placeboevents to occur more frequently in elderly patients than in younger ones, and three of four episodes of hallucinations were treated subjects). Transient elevations in hepatic transaminase levels also occurred in both groups. No subjects were withreported by elderly patients. A reported case of acute delirium associated with ciprofloxacin therapy occurred in a hospitalized drawn because of adverse events. In 16 subjects whose CD4 cell counts ranged from 100/mm 3 to 550/mm 3 and who were elderly patient [106] .
Tendon disorders may also occur more frequently in older taking zidovudine concomitantly, there were no clinically significant differences in adverse clinical or laboratory events bepatients. In the French series [89] of 100 patients with tendon disorders or ruptures, the mean age of the affected patients was tween the levofloxacin and placebo groups, nor did any adverse event require discontinuation of therapy or dosage reduction 63 years, within a range of 25 -84 years. One American case report described bilateral Achilles tendinitis in an 85-year-old
[113]. patient with polymyalgia rheumatica who was receiving both Neutropenic steroid and enoxacin therapy [87] . Caution seems prudent in such situations.
Neutropenic patients may be exposed to higher doses and Results of sparfloxacin clinical trials conducted in Europe more prolonged courses of antibiotic prophylaxis with FQs demonstrated no difference in incidence of drug-related adverse than nonneutropenic patients [114] . Prolonged therapy or an events or rate of treatment discontinuation among the one-third increased dosage may be associated with a higher incidence of of patients who were older than 65 years, vs. among those who adverse events with quinolones. Little safety information on were younger [28] . A recent study investigated the effect of FQs has been derived from studies of neutropenic patients, in age on single-dose pharmacokinetics in healthy young volunwhom occurrence of potential adverse events is confounded by teers (18 -40 years of age) as compared with elderly volunteers many factors. ( §65 years of age) [107] and found no difference in incidence A meta-analysis examined international safety data from 29 of adverse events following an oral dosing of 500 mg of levstudies of neutropenic patients who received FQ therapy (16 ofloxacin. studies) or prophylaxis (13 studies) [114] . The FQs were comNo dosage adjustment is required for either grepafloxacin or pared with several nonquinolone antibiotics or placebo. Rash trovafloxacin for elderly patients. In healthy patients aged 64 - and GI tract disorders were the most common adverse events 81 years who received grepafloxacin (400 mg/d for 7 -9 days), with FQs. The incidence of adverse events was significantly volume of distribution and clearance were decreased, resulting higher (P õ .05) among neutropenic patients receiving treatin a 48% increase in the area under the curve compared to that ment with FQ monotherapy than among nonneutropenic pafor younger subjects [32] . For both agents renal excretion is tients (12.6% vs. 6.4%, respectively). In addition, the overall minimal, with hepatic and biliary systems predominantly inincidence of adverse events was significantly higher (P õ .05) volved in metabolism and clearance [31, 39] . In multiple-dose when FQs were used as therapy, generally at higher doses, clinical trials with trovafloxacin, the overall incidence of drugthan when used as prophylaxis. In all prophylaxis studies except related adverse events in the 27% of patients who were at least one, the incidence of adverse events associated with trimetho-65 years of age was actually less than that among younger age prim-sulfamethoxazole was higher than that with FQs. In studgroups [36] .
ies evaluating monotherapy, there was no statistically significant difference in incidence of adverse events between FQs (12.6%) and comparator agents (10.3%).
HIV-Infected
When FQs were used in combination therapy, the incidence Patients infected with HIV may experience adverse events of adverse events (14.9%) was not significantly different from associated with their disease that are difficult to distinguish that associated with monotherapy (11.6%) or with comparator from those that are drug-induced [108] . Some data suggest agents (13.6%). Nephrotoxicity was more frequent with FQ the frequency of anaphylactic reactions during ciprofloxacin combination regimens than with FQ monotherapy. While the therapy may be increased in HIV-infected patients [45] . In the incidence of adverse events is higher than that observed for cases reported, the reaction usually occurred after the second nonneutropenic patients, the general profile of events is similar, exposure to an FQ [109 -111] . Acute renal failure in one patient and FQs appear to be at least as safe as other antibiotics. with AIDS who was treated with ciprofloxacin has been rePregnant and Nursing Women ported [112] .
In two studies of patients with asymptomatic HIV infection FQs are not recommended for pregnant or nursing women, mainly because of the theoretical potential for causing arthropa- Additional concerns based on preclinical data rable decision to apply for FDA approval only for the mostneeded indication for this agent, i.e., lower respiratory tract include their ability to impair bacterial DNA synthesis through inhibition of DNA gyrase (topoisomerase II) and abortifacient infections. effects when administered at maternally toxic doses [8, 115] . Maternally nontoxic doses of ciprofloxacin administered to Summary pregnant cynomolgus monkeys caused no increase in abortions, nor was there any effect on development of the embryo or
The important advance in antibacterial activity ushered in by fetus [115] . Other animal studies, however, have demonstrated FQs has fortunately been accompanied by a generally excellent fetal wastage and embryotoxic effects such as malformations safety record. Ongoing research in the development of new FQ with large doses of ciprofloxacin, ofloxacin, norfloxacin, troagents is aimed at further improvement in the safety profile, vafloxacin, and temafloxacin [11, 36, 61] .
while maintaining or enhancing antimicrobial efficacy. As new In a clinical study involving 38 pregnant women who reagents become available, certain predictions can be made received either norfloxacin or ciprofloxacin during pregnancy, garding possible adverse events, on the basis of their molecular there was no evidence of increased risk of infant malformations structure. The four newly approved agents demonstrate the or musculoskeletal problems when compared to the outcome importance of an agent's safety profile in selecting an FQ for of a matched control group [116] . Most women in the study therapy. All represent an advance in therapeutic efficacy over were being treated for a urinary tract infection and most were previously available agents, but the adverse event profiles for in the third trimester of pregnancy. Cesarean delivery (45%) sparfloxacin and grepafloxacin are likely to limit their use comand fetal distress (40%) were significantly more common pared with use of levofloxacin and trovafloxacin. among women treated with an FQ, and mean birth weight of Levofloxacin appears to be at least as safe and well tolerinfants born to FQ-treated mothers was 8.5% higher than that ated as other agents in its class. It has demonstrated a low of infants born to mothers in the control group. There was no incidence of GI and CNS adverse events, very little photoevidence of infant musculoskeletal problems. toxicity, and no cardiotoxicity. While the rates of most adIn a recent prospective study, 200 pregnant women exposed verse events with sparfloxacin are similar to or lower than to an FQ (mostly ciprofloxacin or norfloxacin) were matched those with other agents, it is hampered by a relatively high with 200 controls who were treated for various infections with rate of phototoxicity and QT c interval prolongation. The an antibiotic known to be nonteratogenic and nonembryotoxic most frequently reported adverse events with grepafloxacin [117] . Quinolone-treated women had therapeutic abortions at are GI symptoms and taste perversion, particularly at high a higher rate, but rates of congenital malformations and other doses. Grepafloxacin has been associated with QT c interval measures of pregnancy outcome and infant health did not differ prolongation, but the incidence of associated phototoxicity for the two groups. While the authors of this large multicenter appears less than that with sparfloxacin. trial concluded that use of FQs during embryogenesis appeared Trovafloxacin appears to cause an increased rate of mild safe, it seems prudent for pregnant or nursing women to avoid CNS effects, mainly dizziness, but it has not been reported to these drugs unless the potential benefit clearly outweighs the prolong the QT c interval and has a low phototoxic potential. potential risk [8] .
The implications of trovafloxacin's structure with respect to temafloxacin-like adverse events are uncertain, but no problems were noted in ú200,000 subjects in clinical trials. These latest High-Risk FQs FQ additions further advance this group of relatively safe and Some FQs are notable for a relatively high level of toxicity.
highly effective antimicrobials that are now widely used in In addition to temafloxacin, another agent associated with an clinical practice. unexpectedly high incidence of adverse experiences is fleroxacin, a trifluorinated compound [10, 118] . The overall inciAcknowledgment dence of reported adverse events with fleroxacin was 84% in 79 subjects, with severe reactions in 48%. The incidence and
The authors thank Tina Torey, of the Antibiotic Research Clinic severity of adverse events were dose-related; such events oc-(Seattle), for her help in preparing the manuscript. curred in 69%, 85%, and 96% of patients treated with doses of 400 mg, 600 mg, and 800 mg, respectively. The most comAddendum mon events were those involving the CNS and GI tract. Doserelated phototoxicity with fleroxacin was mentioned earlier.
After this manuscript was accepted for publication, additional
This unusually high frequency of adverse events may be related post-marketing surveillance data for trovafloxacin became availto three fluorine atoms in the fleroxacin molecule [10] .
able that revealed the potential for liver enzyme abnormalities Phototoxicity is a problem with sparfloxacin. The reaction is and/or symptomatic hepatitis during short-or long-term therapy avoidable, usually only mild to moderate, and fully reversible.
[36]. In addition, symptomatic pancreatitis was reported. It is recommended that clinicians monitor liver function tests and pancreNevertheless, the manufacturer of sparfloxacin made the admi-/ 9c61$$fe14 01-20-99 07:41:30 cida UC: CID
